EMA Authorised: Nplate (romiplostim) — Amgen Europe B.V.

View source ↗

Summary

EMA authorised marketing of Nplate (romiplostim) for idiopathic thrombocytopenic purpura (ITP) in the European Union. The decision confirms regulatory approval …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• Nplate (romiplostim)

Snippet

Status: Authorised. Therapeutic area: Purpura, Thrombocytopenic, Idiopathic. MAH: Amgen Europe B.V.. Decision date: 04/09/2025